All News

RheumNow Podcast square

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

Jack Cush, MD

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Read Article
PSORIASIS.LH_.jpg

Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis

Jack Cush, MD

Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA).

Read Article
PSS.hands_.Raynauds.jpg (keep)

Tocilizumab in Refractory Skin and Joint Scleroderma

Jack Cush, MD

The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc)  and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization.

Read Article
RheumNow Podcast square

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
myositis, polymyositis, wikipedia

Skin Involvement with HMGCR Necrotizing Myositis

Jack Cush, MD

The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported.

Read Article
FDA.approved.jpg

FDA Approves Anifrolumab in SLE

Jack Cush, MD

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  

Read Article
RheumNow Podcast square

RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)

Jack Cush, MD

How much psoriasis do you need to have in order to have psoriatic arthritis? This plus a review of rheumatology and COVID news from the past week on RheumNow.com.

Read Article
shingles_0.jpg

Shingles Risk with JAK Inhibitors and Other Biologics

Jack Cush, MD

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.

Read Article
Jo1.gottrons.jpg

FDA Approves IVIG in Dermatomyositis

Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).

Read Article
Nail, pitting, psoriasis, onycholysis

Impact of Nail Psoriasis on Psoriatic Arthritis

Jack Cush, MD

Mease and colleagues have shown that psoriatic arthritis (PsA) patients with nail involvement have worse disease and outcomes than those without nail psoriasis.

Read Article
In case you missed it: Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA). https://t.co/2YbLBsFedv https://t.co/OYMJ6Y54UF

Links:

Dr. John Cush RheumNow ( View Tweet)
European Commission approves upadacitinib (Rinvoq)-first JAK Inhibitor for use in adults & adolescents with Moderate to Severe Atopic Dermatitis. UPA is approved for atopic dermatitis in other nations, Russia, Saudi Arabia; pending review in US https://t.co/hiPkJoJCex

Links:

Dr. John Cush RheumNow ( View Tweet)

European Commission has approved bimekizumab (Bimzelx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis. Bimekizumab is a dual IL-17 inhibitor (IL-17A and IL-17F). https://t.co/viRNbx2cbt

Links:

Dr. John Cush RheumNow ( View Tweet)

Psoriasis Prevalence in adults in the United States is 3.0%, indicating that more than 7.5 million adults 20 years or older have psoriasis. Most common in non-Hispanic White individuals; prevalence has not significantly changed since 2003. https://t.co/3yrlPu1GGi

Links:

Dr. John Cush RheumNow ( View Tweet)

In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@wk16, UPA 71% vs DUP 61% https://t.co/5cOoosKyao

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast – Psoriatic Arthritis Without Psoriasis Download wherever you get your podcasts! https://t.co/Ra5f7507XT https://t.co/5WqPCgGVpr

Links:

Dr. John Cush RheumNow ( View Tweet)
Dutch study of 644 t Early Psoriatic Arthritis pts shows that 17% had no psoriasis (PASI = 0), 71% had mild psoriasis (PASI < 7), 9% moderate psoriasis (7–12) and 4% had severe psoriasis (PASI > 12). PASI didnt fluctuate much in 1st year https://t.co/XW3QhJ65Oz

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective cohort study of 1719 Psoriasis only pts (F/U 14721 py) were Rx w/ topicals (81%), cDMARDs (13%), bDMARDs (6%). Overall, 239 patients (14%) developed PsA - Lower risk of PSA if Rx w/ biologics (IRR=0.26 vs topicals; not csDMARDs) https://t.co/BqJWPxG7xf

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 39 studies, 15,673 pts with nail psoriasis = 100% improvement of the Nail Psoriasis Severity Index, ixekizumab was best @ 24 wks (OR 2.98; 95% CI, 1.74-5.10), followed by TNF inhibitor (infliximab, adalimumab). https://t.co/VnhbMPYEV7

Links:

Dr. John Cush RheumNow ( View Tweet)

Impact of Nail Psoriasis on Psoriatic Arthritis Mease and colleagues have shown that psoriatic arthritis (PsA) patients with nail involvement have worse disease and outcomes than those without nail psoriasis. https://t.co/fOiso0EGAK https://t.co/6YREBE2mHg

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×